“One-stop-shop” staging: Should we prefer FDG-PET/CT or MRI for the detection of bone metastases?

Heusner, Till A.; Gölitz, Philipp; Hamami, M; Eberhardt, Wilfried; Eßer, Stefan; Forsting, Michael; Bockisch, Andreas; Antoch, Gerald

doi:10.1016/j.ejrad.2009.10.031

Cited by 43 publications

(28 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although our study did no yield specificity and accuracy, the result is rather similar. Moreover, Heusner et al investigated the diagnostic ability of bone metastasis in non-small cell lung cancer and melanoma and concluded FDG-PET-CT and WB-MRI were equally effective [14].…”

Section: Discussionmentioning

confidence: 99%

Retrospective comparative study between 3T WB-MRI including WB-DWI and 18F-FDG-PET/CT in detection of metastatic disease

Tanaka¹,

Nakanishi²,

Ueda³

et al. 2017

Cancer Rep Rev

View full text Add to dashboard Cite

Purpose: To retrospectively compare the diagnostic accuracy of 18F-FDG-PET/CT (PET-CT) and WB-MRI with WB-DWI (WB-MRI) in various types of metastatic diseases. Materials and methods:There were 26 patients who underwent WB-MRI and PET-CT within a period of one month. The WB-MRI protocols were: sagittal T1WI (Turbo Spin Echo) with TR/TE: 600/ 9.4 (msec), STIR with TR/ TE: 6000/85/240 (msec), coronal T1WI (FLASH) with TR/TE of 120/2.46 (msec) and axial DWI (b-0 and 800) based on STIR with TR/TE/TI of 14000/60/240 (msec). Three radiologists with various lengths of experience were assigned to review the WB-MRI images. The PET-CT reports were reviewed by radiologists with more than 10 years of experience in diagnostic PET-CT images. All patients had a follow-up of more than 6 months by MRI, computed tomography (CT) or PET-CT.Results: A total of 124 gold standard malignant lesions were identified. Regarding WB-MRI, the sensitivity was 68-78% (p=0.059-1.00) and the positive predicted value was 76-84%. With PET-CT, 98 lesions were detected correctly in total and the sensitivity and positive predictive values were 79% and 65%. Concerning only skeletal metastasis, the number of gold standard lesions was 80 in total. Regarding WB-MRI, the sensitivity was 85-93% (p=0.002-0.02) and the positive predicted value was 79-95%. With PET-CT, 61 lesions were detected correctly in total and the sensitivity and positive predictive values were 76% (61/80), 75% (61/81) respectively Conclusion: Although PET-CT and WB-MRI yielded similar overall results in detection of malignant lesions, the performance of WB-MRI in detection of bone metastasis was significantly higher.

show abstract

Section: Discussionmentioning

confidence: 99%

Retrospective comparative study between 3T WB-MRI including WB-DWI and 18F-FDG-PET/CT in detection of metastatic disease

Tanaka¹,

Nakanishi²,

Ueda³

et al. 2017

Cancer Rep Rev

View full text Add to dashboard Cite

show abstract

“…Une analyse par patient aurait montré une détection insuffisante des lésions osseuses dans seulement un quart des cas (un parmi les quatre patients) et il n'y avait aucune conséquence sur le stade Ann Arbor. Cependant, cette faible sensibilité de l'IRM pour les lésions osseuses dans notre étude soulève des interrogations puisque d'après les données de la littérature, la sensibilité de l'IRM devrait être plus élevée [47][48][49][50]. Takenaka et al [51], Fig.…”

Section: Stade Selon Tep-fdgunclassified

Comparaison de l’IRM de diffusion et de la TEP/TDM au FDG dans le bilan des lymphomes

et al. 2012

View full text Add to dashboard Cite

“…These findings indicate that for a reasonable judgment on the favored imaging modality in a certain cancer entity, differentiated studies are indispensible. Both PET/CT and MRI suffer from false-negative results requiring periodic restaging (14).…”

Section: Bone Metastasesmentioning

confidence: 99%

Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma

Buchbender

Heusner²,

Lauenstein³

et al. 2012

J Nucl Med

Self Cite

151

View full text Add to dashboard Cite

Learning Objectives: On successful completion of this activity, participants should be able to describe (1) the advantages and disadvantages of PET/MRI in oncologic applications in comparison to conventional imaging methods and PET/CT; (2) the limitations of PET/MRI compared with invasive staging procedures (biopsy); and (3) the metabolic-anatomic imaging procedure of choice (PET/MRI vs. PET/CT) based on tumor entity and location.Financial Disclosure: The authors of this article have indicated no relevant relationships that could be perceived as a real or apparent conflict of interest. CME Credit: SNM is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing education for physicians. SNM designates each JNM continuing education article for a maximum of 2.0 AMA PRA Category 1 Credit. Physicians should claim only credit commensurate with the extent of their participation in the activity.For CE credit, participants can access this activity through the SNM Web site (http://www.snm.org/ce_online) through August 2013.With integrated whole-body PET/MRI, a novel metabolicanatomic imaging technique recently has been introduced into clinical practice. This review addresses PET/MRI of bone tumors, soft-tissue sarcoma, melanoma, and lymphoma. If PET/ MRI literature is not yet available for some types of tumors, potential indications are based on available PET/CT and MRI data. PET/MRI seems to be of benefit in T-staging of primary bone tumors and soft-tissue sarcomas. With regard to N-staging, PET/MRI can be considered similarly accurate to PET/CT when applied as a whole-body staging approach. M-staging will benefit from MRI accuracy in the brain, the liver, and bone. Imagi ng plays a key role in diagnosis and staging in oncology. Evaluation of local tumor extent and detection of potential locoregional lymph node or distant metastases according to the periodically revised standardized TNM cancer staging system (1) directly affects patient care by defining the most suitable therapy. With integrated wholebody PET/MRI, a new metabolic-anatomic imaging modality has been introduced into clinical practice. Despite the fact that the solution of basic problems, such as adequate MRI-based attenuation correction, is still a work in progress (2), reports on initial clinical experiences with PET/MRI in oncology are already available. In this second part of our review on PET/MRI in oncologic applications, we summarize the available first experiences with PET/ MRI in bone tumors, soft-tissue sarcoma, melanoma, and lymphoma. In fields where PET/MRI data are lacking, we outline the potential role of PET/MRI on the basis of the PET/CT and MRI literature. To provide further information on PET/MRI, we refer to our own unpublished experiences with PET

show abstract

“One-stop-shop” staging: Should we prefer FDG-PET/CT or MRI for the detection of bone metastases?

Cited by 43 publications

References 33 publications

Retrospective comparative study between 3T WB-MRI including WB-DWI and 18F-FDG-PET/CT in detection of metastatic disease

Retrospective comparative study between 3T WB-MRI including WB-DWI and 18F-FDG-PET/CT in detection of metastatic disease

Comparaison de l’IRM de diffusion et de la TEP/TDM au FDG dans le bilan des lymphomes

Oncologic PET/MRI, Part 2: Bone Tumors, Soft-Tissue Tumors, Melanoma, and Lymphoma

Contact Info

Product

Resources

About